Company intelligence / Profile preview
Shanghai Kangdai Biomedical Technology
Shanghai, Shanghai Shi, Chinakandatech.cn ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Shanghai Kangdai Biomedical Technology has its most advanced project, KD6001, in Phase 1 for advanced solid tumors, with another IND-approved project (KD6005) for rheumatoid arthritis. Early clinical data focuses on safety, tolerability, and pharmacokinetics in solid tumor patients.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Monoclonal antibodyBiologic
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Shanghai Celgen Bio-pharmaceutical
Beyond the preview
Go deeper on Shanghai Kangdai Biomedical Technology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shanghai Kangdai Biomedical Technology.